国际妇产科学杂志

国际妇产科学杂志 ›› 2014, Vol. 41 ›› Issue (3): 240-243.

• 综述 • 上一篇    下一篇

曲贝替定应用于复发性卵巢癌治疗进展

赵建国，曲芃芃   

  1. 300070 天津医科大学研究生院（赵建国）；天津市中心妇产科医院（赵建国，曲芃芃）
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2014-06-15 发布日期:2014-06-15
  • 通讯作者: 赵建国

Progress of Treatment in Recurrent Ovarian Cancer with Trabectedin

ZHAO Jian-guo，QU Peng-peng   

  1. Graduate School of Tianjin Medical University，Tianjin 300070，China（ZHAO Jian-guo）；Tianjin Central Hospital of Gynecology Obstetrics，Tianjin 300100，China（ZHAO Jian-guo，QU Peng-peng）
  • Received:1900-01-01 Revised:1900-01-01 Published:2014-06-15 Online:2014-06-15
  • Contact: ZHAO Jian-guo

PDF (PC)

5096

摘要： 曲贝替定（Yondelis■，Trabectedin）是一种新的非铂类抗肿瘤药物，有独特的抗肿瘤机制，不良反应主要为可逆性肝脏损害。Trabectedin的心脏毒性低，可以和蒽环类抗肿瘤药物联合应用，目前已应用于复发性卵巢癌的治疗。临床可选用的治疗方案有单药3周方案、单药周疗和联合蒽环类药物方案，其中联合方案疗效最好。Trabectedin对铂类敏感的复发性卵巢癌有较好的疗效，特别是对无铂间隔期（treatment-free interval，TFI）为6~12个月的复发性卵巢癌疗效显著，但对铂类耐药及难治性卵巢癌的疗效不明显。应用Trabectedin可延长TFI，为以后再次进行铂类药物治疗创造条件。

关键词: 卵巢肿瘤, 癌, 抗肿瘤联合化疗方案, 曲贝替定, 无铂间隔期

Abstract: Trabectedin （Yondelis■） is a new non-platinum antineoplastic drug with a unique antitumor mechanism. It′s main side effect is the reversible liver injury, and it′s cardiac toxicity is low. Trabectedin can be applied with anthracycline-based drugs in the treatment of recurrent ovarian cancer. The optional treatment clinically include：single drug 3 weeks plan，single drug weekly therapy，combined anthracycline-based drugs，the best effect is the in combinational scheme. Trabectedin make satisfied curative effect in platinum sensitive recurrent ovarian cancer，especially treatment-free interval （TFI） 6-12 month. The platinum resistance and refractory ovarian cancer curative effect is not obvious. Application of Trabectedin can extend the TFI ,as to create conditions for using platinum drugs again.

Key words: Ovarian neoplasms, Carcinoma, Antineoplastic combined chemotherapy protocols, Trabectedin, Platinum-free interval